Obstructive sleep apnea and longitudinal Alzheimer's disease biomarker changes. Issue 6 (22nd February 2019)

• Record Type: Journal Article
• Authors: Bubu, Omonigho M; Pirraglia, Elizabeth; Andrade, Andreia G; Sharma, Ram A; Gimenez-Badia, Sandra; Umasabor-Bubu, Ogie Q; Hogan, Megan M; Shim, Amanda M; Mukhtar, Fahad; Sharma, Nidhi; Mbah, Alfred K; Seixas, Azizi A; Kam, Korey; Zizi, Ferdinand; Borenstein, Amy R; Mortimer, James A; Kip, Kevin E; Morgan, David; Rosenzweig, Ivana; Ayappa, Indu; Rapoport, David M; Jean-Louis, Girardin; Varga, Andrew W; Osorio, Ricardo S
• Is Part Of: Sleep. Volume 42:Issue 6(2019)
• Publication Date: 2019-02-22
• Subjects: obstructive sleep apnea -- Alzheimer's disease -- longitudinal study -- CSF biomarkers -- brain amyloid PET -- Aβ42 -- T-tau -- P-tau; Sleep -- Physiological aspects -- Periodicals; Sleep disorders -- Periodicals; Sommeil -- Aspect physiologique -- Périodiques; Sommeil, Troubles du -- Périodiques; Sleep disorders; Sleep -- Physiological aspects; Sleep -- physiological aspects; Sleep Wake Disorders; Psychophysiology; Electronic journals; Periodicals; 616.8498
• DOI: 10.1093/sleep/zsz048
• Languages: English
• ISSNs: 0161-8105

Abstract

Abstract: Study Objectives: To determine the effect of self-reported clinical diagnosis of obstructive sleep apnea (OSA) on longitudinal changes in brain amyloid PET and CSF biomarkers (Aβ42, T-tau, and P-tau) in cognitively normal (NL), mild cognitive impairment (MCI), and Alzheimer's disease (AD) elderly. Methods: Longitudinal study with mean follow-up time of 2.52 ± 0.51 years. Data were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Participants included 516 NL, 798 MCI, and 325 AD elderly. Main outcomes were annual rate of change in brain amyloid burden (i.e. longitudinal increases in florbetapir PET uptake or decreases in CSF Aβ42 levels); and tau protein aggregation (i.e. longitudinal increases in CSF total tau [T-tau] and phosphorylated tau [P-tau]). Adjusted multilevel mixed effects linear regression models with randomly varying intercepts and slopes was used to test whether the rate of biomarker change differed between participants with and without OSA. Results: In NL and MCI groups, OSA+ subjects experienced faster annual increase in florbetapir uptake ( B = .06, 95% CI = .02, .11 and B = .08, 95% CI = .05, .12, respectively) and decrease in CSF Aβ42 levels ( B = −2.71, 95% CI = −3.11, −2.35 and B = −2.62, 95% CI = −3.23, −2.03, respectively); as well as increases in CSF T-tau ( B = 3.68, 95% CI = 3.31, 4.07 and B = 2.21, 95% CI = 1.58, 2.86, respectively) and P-tau ( B = 1.221, 95% CI = 1.02, 1.42 and B = 1.74, 95% CI = 1.22, 2.27, respectively); compared with OSA− participants. No significant variations in the biomarker changes over time were seen in the AD group. Conclusions: In both NL and MCI, elderly, clinical interventions aimed to treat OSA are needed to test if OSA treatment may affect the progression of cognitive impairment due to AD.